Development of Novel Antimicrobial Resistance Agents
$5,160,457N01FY2011AINIH
Achaogen, Inc., South San Francisco CA
Investigators
Abstract
This contract supports the advanced development of a novel antibacterial for the treatment of Gram-negative pathogens. The scope of work for this contract includes discovery, preclinical/non-clinical development activities, IND-enabling activities, and Phase I clinical trials.
View original record on NIH RePORTER →